

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|                       |                           |                      |
|-----------------------|---------------------------|----------------------|
| First Applicant:      | Serge Louis Boulet et al. | Group Art Unit: 1626 |
| Serial No.:           | 10/597,835                | Sun Jae Y Loewe      |
| Application Date:     | February 18, 2005         | Conf No.: 6937       |
| US Nat'l Entry        |                           |                      |
| Date (if applicable): | August 9, 2006            |                      |
| For:                  | PHARMACEUTICAL COMPOUNDS  |                      |
| Docket No.:           | X-16288                   |                      |

**STATEMENT UNDER 37 CFR 1.97(e)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit the following statement under §1.97(e):

I, Mark A. Winter, hereby state that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Applicants request consideration of this information.

Respectfully submitted,  
/Mark A. Winter/

Mark A. Winter  
Agent for Applicants  
Registration No. 53,782  
Phone: 317-276-5362

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
September 11, 2008